Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer-Reference-Cited by-同舟云学术

Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer

Published:2017-05-09 Issue:18 Volume:317 Page:1844
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Jänne Pasi A.¹,van den Heuvel Michel M.²,Barlesi Fabrice³,Cobo Manuel⁴,Mazieres Julien⁵,Crinò Lucio⁶,Orlov Sergey⁷,Blackhall Fiona⁸,Wolf Juergen⁹,Garrido Pilar¹⁰,Poltoratskiy Artem¹¹,Mariani Gabriella¹²,Ghiorghiu Dana¹²,Kilgour Elaine¹³,Smith Paul¹²,Kohlmann Alexander¹²,Carlile David J.¹²,Lawrence David¹²,Bowen Karin¹⁴,Vansteenkiste Johan¹⁵

Affiliation:

1. Lowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts

2. Department of Thoracic Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands

3. Multidisciplinary Oncology and Therapeutic Innovations Department, Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille, France

4. Department of Medical Oncology, Hospital Universitario Málaga General, Instituto de Investigación Biomédica de Málaga, Malaga, Spain

5. Pulmonology Department, Toulouse University Hospital, Toulouse, France

6. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Istituto di Ricovero e Cura a Carattere Scientifico Meldola, Italy

7. Department of Medicine, Pavlov Medical University, St Petersburg, Russia

8. Manchester University and Christie Hospital NHS Foundation Trust, Manchester, United Kingdom

9. Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany

10. Medical Oncology Department, University Hospital Ramon y Cajal, Madrid, Spain

11. Department for Clinical and Preclinical Trials, Petrov Research Institute of Oncology, St Petersburg, Russia

12. AstraZeneca, Cambridge, United Kingdom

13. AstraZeneca, Macclesfield, United Kingdom

14. AstraZeneca, Gaithersburg, Maryland

15. Respiratory Oncology Unit, Department of Respiratory Diseases, University Hospital Katholieke Universiteit Leuven, Leuven, Belgium

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 276 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. KRAS G12C-mutant driven non-small cell lung cancer (NSCLC);Critical Reviews in Oncology/Hematology;2023-12

2. Efficacy and toxicity of drugs targeting KRAS ^G12C mutation in non-small cell lung cancer: a meta-analysis;Expert Review of Anticancer Therapy;2023-11-18

3. The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC;Experimental Hematology & Oncology;2023-11-04

4. The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS^G12D-driven non-small cell lung cancer;2023-09-22

5. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor;Frontiers in Pharmacology;2023-09-21